Cerebral Organoid Model

📖 Wiki Page

model667 wordssynced 2026-04-02

Cerebral organoids represent a revolutionary in vitro model system that recapitulates aspects of human brain architecture and function in three dimensions. These self-organizing structures provide unprecedented access to human neural development and disease mechanisms.

Derivation Methods

...

Derivation Methods

Mermaid diagram (expand to render)

Protocols for Cerebral Organoid Generation

| Protocol | Developer | Key Features | Applications |
|----------|-----------|---------------|--------------|
| Lancaster | Lancaster et al., 2013 | Matrigel embedding, spinning flask | Cortical development |
| Quadrato | Quadrato et al., 2017 | Improved maturation, single-cell | Safety/toxicity screening |
| Bhaduri | Bhaduri et al., 2020 | AP-mediated patterning | Regional specification |
| Yoon | Yoon et al., 2019 | Vascularized organoids | Ischemia models |

Differentiation Timeline

Days 0-5: Embryoid body formation from iPSCs/ESCs

Days 5-10: Neural ectoderm induction via BMP/SMAD inhibition

Days 10-20: Neuroepithelial cyst formation

Days 20-60: Neural progenitor expansion, early neuronal differentiation

Days 60-100+: Neuronal maturation, synapse formation, glial differentiation

Cellular Composition

Neuronal Populations

Cortical excitatory neurons: Glutamatergic pyramidal neurons
Interneurons: GABAergic inhibitory neurons (when properly patterned)
Subcortical neurons: Dopaminergic, serotonergic neurons (with regional patterning)

Glial Cells

[Astrocytes](/cell-types/astrocytes): Emerge after day 60, perform metabolic support
Oligodendrocytes: Myelinating glia (day 80+ with appropriate differentiation)
Microglia: Rare in standard protocols; improved with myeloid co-culture

Structural Features

Ventricular zones: Neural progenitor cycling zones
Cortical plate: Layered neuronal architecture
Subventricular zones: Secondary progenitor pools
Synaptic networks: Functional excitatory and inhibitory connections

Disease Modeling Applications

Alzheimer's Disease Modeling

Cerebral organoids enable study of AD-relevant pathology in human tissue:

Amyloid pathology: APP/PSEN1 organoids develop Aβ plaques and associated changes

Tau pathology: Hyperphosphorylated tau in neuronal processes

Neuroinflammation: Glial responses to amyloid deposition

Synaptic dysfunction: Impaired LTP, reduced synaptic markers

Parkinson's Disease Modeling

| PD Model | Approach | Phenotype |
|----------|----------|-----------|
| LRRK2 G2019S | Gene-edited iPSCs | Altered neuronal morphology, stress sensitivity |
| SNCA triplication | Patient-derived | Increased α-synuclein aggregation |
| Idiopathic | Patient-derived | Mitochondrial dysfunction, metabolic changes |
| Mitochondrial | Complex I inhibitors | Dopaminergic neuron vulnerability |

Other Neurodegenerative Diseases

Huntington's disease: Mutant HTT aggregation, selective vulnerability
Frontotemporal dementia: Tau pathology, neuronal loss
Amyotrophic lateral sclerosis: TDP-43 pathology, motor neuron vulnerability

Research Applications

Drug Testing

Cerebral organoids serve as preclinical testing platforms:

Efficacy testing: Rescue of disease phenotypes (aggregation, neuronal survival)

Toxicity assessment: Human-specific adverse effects

Penetration studies: Blood-brain barrier drug penetration (with vascular organoids)

Combination therapy: Multi-target drug interactions

Mechanism Studies

Development: Human-specific developmental processes
Infection: Zika virus, SARS-CoV-2 neuropathogenesis
Circuit dysfunction: Network activity abnormalities
Cell-cell interactions: Glial-neuronal crosstalk

Advantages and Limitations

Advantages

Human tissue: Human cells in a 3D context
Complex architecture: Recapitulates brain region organization
Long-term culture: Can be maintained for months
Patient-specific: Disease modeling from individual patients
Scalable: Multiple organoids from single iPSC line

Limitations

Variability: Organoid-to-organoid variation
Lack of vasculature: Limits size and maturity (unless vascularized)
Missing cell types: Microglia, oligodendrocytes often absent
Incomplete maturation: Fetal-like rather than adult-like
Ethics: Some concerns about consciousness-like activity

Technical Considerations

Standardization

Single-cell sequencing: Define cell type composition
Functional assays: Calcium imaging, multi-electrode arrays
Biochemistry: Protein/RNA analysis from pooled organoids
Morphology: Histology, confocal imaging

Best Practices

Use validated iPSC lines with regular karyotyping

Include proper controls (isogenic, CRISPR-corrected)

Characterize organoids at multiple timepoints

Report differentiation efficiency and variability

Account for batch effects in experimental design

Related Models

[iPSC-derived neurons](/models/ipsc-derived-dopaminergic-neurons) — 2D neuronal cultures](/models)
[3D neural spheroids](/experiments/multiscale-protein-aggregation-modeling) — Simplified 3D models](/models)
[Brain-on-a-chip](/technologies.md) — Microfluidic systems with organoids

References

[Lancaster et al., 2013 - Cerebral organoids model brain development](https://doi.org/10.1038/nature12521)

[Quadrato et al., 2016 - Single-cell genomics of human brain organoids](https://doi.org/10.1038/nature21068)

[Sloan et al., 2017 - 3D culture model of Alzheimer's disease](https://doi.org/10.1038/s41598-017-04867-1)

[Bhaduri et al., 2020 - Cellular diversity in human brain organoids](https://doi.org/10.1038/s41586-020-2582-4)

[Yoon et al., 2019 - Vascularized brain organoids](https://doi.org/10.1038/nature25756)

Pathway Diagram

The following diagram shows the key molecular relationships involving Cerebral Organoid Model discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →